Recurrent Pneumothorax after Etanercept Therapy in a Rheumatoid Arthritis Patient: A Case Report / 전남의대학술지
Chonnam Medical Journal
;
: 115-118, 2014.
Article
in English
| WPRIM
| ID: wpr-75445
ABSTRACT
The use of anti-tumor necrosis factor (anti-TNF) agents for rheumatoid arthritis (RA) patients who are refractory to disease-modifying anti-rheumatic drugs is gradually increasing. Etanercept is the first anti-TNF agent to be approved for RA treatment and is also the most widely used. However, aggravation of interstitial lung disease after etanercept treatment in RA patients has been reported recently. We report the first case of recurrent spontaneous pneumothorax with progression of interstitial lung disease after initiating etanercept therapy. The withdrawal of etanercept and a change to adalimumab, a different class of TNF inhibitor, achieved clinical stabilization.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pneumothorax
/
Arthritis, Rheumatoid
/
Lung Diseases, Interstitial
/
Antirheumatic Agents
/
Adalimumab
/
Etanercept
/
Necrosis
Limits:
Humans
Language:
English
Journal:
Chonnam Medical Journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS